Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Comment on: "a simple and valid tool distinguished efficacy from effectiveness studies".

Spigt MG, Kotz D.

J Clin Epidemiol. 2007 Jul;60(7):753-5. Epub 2007 Feb 20. No abstract available.

PMID:
17573995
2.

A simple and valid tool distinguished efficacy from effectiveness studies.

Gartlehner G, Hansen RA, Nissman D, Lohr KN, Carey TS.

J Clin Epidemiol. 2006 Oct;59(10):1040-8. Epub 2006 Aug 4.

PMID:
16980143
3.

The design and analysis of randomized controlled trials of treatments for lower urinary tract symptoms.

Peters TJ.

BJU Int. 2000 Mar;85 Suppl 1:3-9. Review. No abstract available.

4.

A simple sample size formula for analysis of covariance in randomized clinical trials.

Borm GF, Fransen J, Lemmens WA.

J Clin Epidemiol. 2007 Dec;60(12):1234-8. Epub 2007 Jun 6.

PMID:
17998077
5.

Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings.

Bedard PL, Krzyzanowska MK, Pintilie M, Tannock IF.

J Clin Oncol. 2007 Aug 10;25(23):3482-7.

PMID:
17687153
6.

How should treatment results from clinical practice be reported?

Rowbotham MC.

Pain. 2008 Sep 15;138(3):475-6. doi: 10.1016/j.pain.2008.08.003. Epub 2008 Aug 22. No abstract available.

PMID:
18722713
7.

Comment on the CADISS trial protocol.

Warlow CP.

Int J Stroke. 2007 Nov;2(4):291. doi: 10.1111/j.1747-4949.2007.00162.x. No abstract available.

PMID:
18705932
8.

Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?

Rubinstein LV, Dancey JE, Korn EL, Smith MA, Wright JJ.

J Natl Cancer Inst. 2007 Oct 3;99(19):1422-3. Epub 2007 Sep 25. No abstract available.

PMID:
17895470
9.

Blinded sample size reestimation in non-inferiority trials with binary endpoints.

Friede T, Mitchell C, Müller-Velten G.

Biom J. 2007 Dec;49(6):903-16.

PMID:
17726715
11.

Primer on group randomized trials..

Beach ML.

Eff Clin Pract. 2001 Jan-Feb;4(1):42-3. No abstract available.

PMID:
11234186
12.

Pitfalls in the design and analysis of efficacy trials in subfertility.

Daya S.

Hum Reprod. 2003 May;18(5):1005-9. No abstract available.

PMID:
12721177
13.

Open-label surgical trials for Parkinson disease: time for reconsideration.

Alterman RL, Tagliati M, Olanow CW.

Ann Neurol. 2011 Jul;70(1):5-8. doi: 10.1002/ana.22453. Review. No abstract available.

PMID:
21786295
14.

The ethics of sample size: the whole picture should be considered.

Schouten HJ.

J Clin Epidemiol. 2003 Feb;56(2):206-7; author reply 207-8. No abstract available. Erratum in: J Clin Epidemiol. 2003 Apr;56(4):394.

PMID:
12654417
15.

Contrast-induced nephropathy: we need all the data to discern the truth.

Barrett BJ.

Am J Kidney Dis. 2009 Oct;54(4):587-9. doi: 10.1053/j.ajkd.2009.06.011. No abstract available.

PMID:
19781450
16.

Clinical trials. Simple megatrials are not sufficient.

Barer D.

BMJ. 1999 Apr 24;318(7191):1138. No abstract available.

17.

Re: Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non small-cell lung cancer.

Leo F, De Pas T, Catalano G, Piperno G, Curigliano G, Solli P, Veronesi G, Petrella F, Spaggiari L.

J Natl Cancer Inst. 2007 Aug 1;99(15):1210; author reply 1210-1. Epub 2007 Jul 24. No abstract available.

PMID:
17652281
18.

Comment on "Why analysis of variance is inappropriate for multiclinic trials" by David Salsburg.

Shih WJ.

Control Clin Trials. 1999 Oct;20(5):469-71. No abstract available.

PMID:
10503806
19.

Clinical trials: a summary.

Wilhelmsen L, Held P, Wedel H.

J Intern Med. 2004 Oct;256(4):284-7. Review. No abstract available.

20.

Methodological errors in staphylococcal equivalence study.

Richards J, Black J, Marshall C.

Clin Infect Dis. 2005 Mar 1;40(5):771-2; author reply 772-3. No abstract available.

PMID:
15714433

Supplemental Content

Support Center